Reddit Posts
Mentions
Cool. I figured some natural correction on momentum that big probably played into it. I should look into it more. SLS is a pretty significant share of my portfolio, and I’ve got much smaller positions in NUVB and CLYM (both of which have had reasonable gains and still have room to keep going). I’m pretty excited to see what SLS does. Thanks for replying.
Can someone please trigger NUVB? K thanks bye.
Nobody mentioned Nuvation Bio? NUVB
Take a look at NUVB. Good company, great CEO, trials have been promising, and it was never pumped and dumped. If you’re into cancer treatment and biotech plays. Still early, PTs increased to 12-14$ I believe and it just dipped heavy back to the $5-6 range I believe
Fuck yeah - NUVB wins, congrats!
I made like 150-180k on NUVB so perhaps I wouldn’t have had the $$. Missed trades but also missed opportunities elsewhere
I am holding. I think the reason in price change is market dynamics, fundamentals have not changed. The patients uptake was 219 in Q4. This aligns perfectly with OP’s bet. As per some models, this (not taking into account potential rise in patient numbers) implies at least ~400 million peak revenue with patient stacking (not including ex-US revenue). Multiply that by 4, you get 1,6 billion plus some pipeline optionality. With these prices, you are buying safusidenib and all the potential rise in patient uptake for ~700 million. With results that safusidenib is showing, that is a bargain. As per market dynamics, i think NUVB had great momentum in december, everyone was waiting for the deal which would bring in lets say 300 million, rising the market cap by 10% (easy money - why take profit before that). So no one really took profits of the massive rise in valuation. Because the deal did not come through in december, folks started to get nervous and we went from almost 10 toward 8. Then the news of the deal came which was “only” 60 million or so upfront payment, not what people were looking for. Combine that with some profit taking and usual biotech in-between-catalysts decline, and here we are. I think Hung will counter all those arguments today at JPM conference. The thing to look for is how many of new drug prescriptions are done in first line (those contribute to patient stacking the most) and how is community uptake doing (there most patients are given the drug, more than academic centers). Hung knows what he is doing and he did not sell at almost 10. Lets ride!
Anyone know why NUVB dropped 20% today? I haven’t found any news to support it
ohhh glad to see there are still some people sticking to nuvb. *like usual this is not financial advice, i am just a regard who likes stocks* my personal take is i think it's oversold for a few reasons: 1) sell the news: EU partnership news is done so we now go back to pre-hype 2) EU deal seems low compare to other deals: \~50M upfront payment is peanuts if you compare it to other similar deal in oncology which is usually sitting at 150M+ 3) analysts downrating NUVB, yes those same analysts who didn't understand the potential of IBTROZI at the time of the first DD. 4) only saw one news talking about safety issues related to IBTROZI ok now let's talk about why i think it's oversold and why this could be an opportunity for long term bag holders: 1) Future forecast **does not assume anything related to EU** **sales** (correct me if i am wrong) 2) only 2 out of 130ish people dropped from clinical study in ibtrozi 3) who trusts analysts anyway? this for ibtrozi alone! not even counting on a Safusidenib approval or good data at all finally, David is not a fan of forecasts. last earning he didn't give guidance which caused the stock to tank post earnings even though the earnings were good. i will be tuning in tomorrow to listen to David's take on it your thoughts on it would be appreciated :)
I kept rolling them and my ETHA calls. I had already made 300% on Etha Dec calls and I was continually rolling GLD and SLV calls. I had a 150% gain an figured it was going tank. It did tank but took a month breather and continued rising. It’s not awful. I did buy NUVB in the 3s and sold recently above 9 so I still made money. But the SLV move is generational
Hey asagi bro, don’t wanna spam NUVB post with other stuff, but $MIST just had the same kind of pattern that NUVB had, with a fall in stock price after FDA approval. This again puts us in the position to evaluate the future proepects of a relatively derisked stock and invest with less speculation, just as it happened with NUVB. I took a small initial position but I am very interested in what you might say about it. I will do some more research in the upcoming days.
This reminds me a lot of NUVB. I made a call 2 months ago because there were rumors of big catalysts upcoming in december (has now almost doubled $3 to $9 in a week). I’ll check it out. Ik everyone hates dipsticks but I personally love them. Especially when they’re for great causes like this one. I am also heavy in on SLS, the AML treatment with their data also releasing very soon (my favorite stock).
careful in this bull market. congrats though. i rarely do options however made some great $ from NUVB releasing data last week, and have options for SLS (releasing their data soon). what current options do you have now?
i was able to turn my initial ~30-50k -> 100k (by the time of this post) -> 300k then with some weight change between NUVB and my other investment PACS at the right time it went to 1.5M. not realized gain though since i am still holding so i can lose it all
NUVB stock??? A winner 🐂📈
Starting off take this post as you will, I’m no expert, I’m just a guy that likes to research companies and enjoys the thrill. I got into NUVB at 1.83 and now took some profits and put into these other two. First off is ABSI it feels a lot like NUVB and it’s going to be for long term play, due to if trials go well it could be the future of modern medicine. Second is VIVK, I see a lot of people throwing out info on it to try to get a pump, I am not not trying to get pump and dump, i mean of course I wouldn’t mind cashing if it does but I believe with everything VIVK has going on right now that it could potentially be the holy grail or then again could be nothing. I’ve read a lot of mixed reviews on VIVK, I’ve read a lot of good and bad facts about it. I just think they have finally got it figured out and are about to start pumping money right out of the ground. Could I eat my words in a day/week/month possibly but at the price it’s sitting at right now for everything they have to offer, it’s almost like losing if I don’t buy it lol I wouldn’t put anything in it you’re not prepared to lose but through a 100 in and see where it takes you. Don’t go throw your bag at these stocks as I stated above I’m not an expert, but I would recommend doing you’re own research on these two and if your gut tells you that you can see a profit then awesome.
this dd made everything possible, for that reason, i will hold solid on NUVB and the promises it holds
I knew cash gang was the answer. Held very little overnight. Did some put plays today during the dump for a small amount of green. Now only holding some DEC calls for NUVB which I'll accumulate.
made my first million today, thanks $NUVB!! to the 2 digits we go
Sold my NUVB $7.50 calls today for a nice 150% gain. Just bought back in for an overnight hold. The CEO has an amazing bio. One company he started he sold to Pfizer for 14B.
Good time to enter NUVB on this dip
Dang. Really glad I held on to NUVB lol. I literally can't remember why I got it, just that I told myself to hold long. What's the news and why is it good? Where we think the train gonna stop?
look at NUVB which I caught over here on WSB. I took all profits after it went up 30%, then jumped another 50% today.wild
been in it with you a while. Congrats man. Random thought though - is volume going to squeeze this? Idk what share dilution looks like on NUVB, but volume is still climbing fast.
Out of FRGT with +18%! holding NUVB for next leg up!
Any reason NUVB is rocketing today?
What is this weird ass shit. No one want NUVB calls? https://preview.redd.it/pmqpi817bu0g1.jpeg?width=1206&format=pjpg&auto=webp&s=12f9f4a60c9102bea7afdd4e0023944e69640b0d
Anyone else buy NUVB when it got posted here a couple months ago? It’s 🔥
[https://finance.yahoo.com/sec-filing/NUVB/0001193125-25-262727\_1811063/](https://finance.yahoo.com/sec-filing/NUVB/0001193125-25-262727_1811063/)
I google the phrase x stock prediction and read from any source that doesn't make me sign up to anything... I hear about the news regarding earnings reports and things like that here on reddit. NUVB has a 100 percent buy rating BTW! It's a bit high as of the past three days but there might be a dip, and i'm still buying either way
NUVB definitely needs more of a crowd, especially with positive earnings coming next week.
NUVB 😎 Early Christmas gift!
i'd like to take some time to answer recurring questions: \- until when we are holding? i can talk about the "fair value" of the company which is definitely > 10$. i can't tell you when exactly to sell, i can tell you when i'll be selling which i will when that day comes. \- info about safusidenib? the thing about biotech is that info is rarely shared i.e you won't know exactly when something happens. you pretty much have to wait for company info unless you are an insider.| so like every retail, i'll have to wait for the earnings/news to know more about how that drug is comparing against the other one \- the stock pumped, is it a good time to get in? think of about your risk tolerance, are you fine with losing it all? if yes, get in. if not, don't. \- is the stock fair priced? wallstreet seems to think it is still undervalued, i believe so too but what do i know? i am just a regard who likes stocks. \- i got in early, is it a good time to sell? i usually sell whenever i am satisfied/need the money. for NUVB it's more tricky since i almost fully ported my retirement account on this. hence selling doesn't give me access to the money immediately at the very list \- i like to do trades in X months time frame how should i play it? i don't know, i don't trade. sometimes, if i need some money and i believe in a stock, i would roll out the option to a higher strike price. In the process, i cash in some money which helps doing other trades. \- i am scared, i'll lose my gains, should i sell? yes because you are too attached to your gains. my portfolio swings like crazy but i am an expert diamond holder. See you Monday 4:30 when the shift at Wendy's starts
NUVB. Q3 report on Monday. Phase 2-study this quarter. Insiders are in, shorts will be struggling to cover.
NUVB ! Short squeeze next week…
Anyone got NUVB calls? Biotech is so bad it might be good. I mean for the regarded investors like us. And they've been growing better than pimples on a teenager
Anyone else in NUVB !?
NUVB ! Shorts will be squeezed on Monday. (Earnings report). Phase 2 Study on Safusidenib coming up this quarter. Ibtrozi is already in business with strong growth. Insiders hold 19% of shares. CEO has 59M shares. This will pop!
Dont miss to load up NUVB before Q-report on Monday! The short squeeze can be a fact! Insiders hold 19% of shares. CEO has 59M shares. Short interest 31% and they are gonna burn. Besides the earnings report Phase 2 Study on Safusidenib coming up this quarter. Ibtrozi is already in business with strong growth! This will pop to 15-20$ before Christmas🤶Thank me later 😎
Dont miss NUVB before Q-report on Monday! The short squeeze can be a fact! Insiders hold 19% of shares. CEO has 59M shares. Short interest 31% and they are gonna burn. Besides the earnings report Phase 2 Study on Safusidenib coming up this quarter. Ibtrozi is already in business with strong growth! This will pop to 15-20$ before Christmas🤶
NUVB Will skyrocket next week! Load up before. Insiders hold 19%, CEO hold 59 million shares. Short squeeze is a fact when earnings are published on Monday.
Well done. I have shares. Its a slight gamble with options, might have bought them too if it wasnt tied to NUVB and GAP which have been very profitable. For now, path has good momentum to go to 18 - 20 if AI doesnt dump with tech earnings
Loading up on NUVB before earnings
I’ve been in shares and options on NUVB since around $2.30 range. I’m extremely bullish on this one. It’s been great so far.
If I may add some of my thoughts: the company NUVL, which competes with NUVB to some extent, has a market cap of 6,7 billion even without an FDA approved drug! One of their drugs, zidesamtinib, is a competitor of Ibtrozi. However, I don’t think NUVL’s valuation is based on zidesamtinib (in fact I think this drug is in trouble because of Ibtrozi). I’d say that their huge valuation is a result of the potential other drugs in their pipeline have. With that being said, I think that NUVB, with the potential that safusidenib has (in terms of total adressable market etc.), can reach pretty decent market cap just based on safusidenib’s potential (not to mention the fact they already have an FDA approved drug, contibuting to their competences). Also, does anyone know more about safu? The current phase 3 study is for high grade glioma, but David will try to go for the low grade as well if I remember correctly.
How are you expecting things to shape up for earnings ?. NUVB has been climbing like fucking crazy so far.
NUVB is going wild 🙈
NUVB Q2 launch of its drug should have put it to 7 min and it’s pending Q3 into double digits. It’s about to announce a pivotal H2H to steal a 2B revenue market and that’s got exactly 0 reflection in the current SP.
NUVB has solid fundamentals. Look up the DD on WSB from about two months ago.
that was the point of my DD to show this: "during HC, David **claim** that they are in discussion with the FDA to go for a Head-to-Head trial against **vorasidenib** * Clear intention of showing safusidenib superiority * They could capture a \~6B market if doing so moving their valuation by a whole bunch." This is substantial, because it will bring the valuation of NUVB way way higher. If you look at all the articles NONE were mentioning that fact but the listeners of the HC could hear that. So i hope during the earnings we would get some information related to that. If we do it will soar past 5$ for sure. You might have noticed: overall market is down, not NUVB. You also might have noticed: the price of NUVB is actually relatively stable (institutions hold it and wait for news unlike degenerates like us) I am growing my position as cash comes in
Any ideas on why NUVB is spiking today? Im not finding anything on it
https://www.youtube.com/live/YK6PdevO27w?si=iBhsZ0WpzJbdewFy A proper NYSE welcome for NUVB
Ready to buy the dip Especially $GOOG $TSM Also watching $AVGO $NUVB $BGM
I’ve had this on a watchlist for 4 months. No news and 3x volume today… Unless someone has the scoop, I’m wondering if it’s being pulled up by the PFE jet stream. a lot of bio tech and healthcare seemed to move over the last 48 hours on the Pfizer news. $NTLA, $ABCL, $NUVB (yesterday), $MRNA, $NVAX, $MERCK… all up.
Wants to get everyones thoughts. Whats a better move for NUVB, sell partial and hold before earnings or hold before earnings and depend on the earnings.
Intriguing… look at NUVB (trust in 3/26 $5C ) and NTLA - long long
Just in case anyone is following me- nothing interesting here for me. I still have: CHRS, ANAB, NUVB, AUTL,HRTX, SPRY, PHAT. Will buy back BEAM, it was a mistake to sell it.
BREAKING News: NUVB IBTROZI is approved in Japan. i mentioned it in the DD, but i also expect sales to go on fast over there. the reason? Sauvage worked at Sanofi Japan and probably has a good book of contact. [https://investors.nuvationbio.com/news/news-details/2025/Nuvation-Bio-Receives-Approval-from-Japans-Ministry-of-Health-Labour-and-Welfare-for-IBTROZITM-for-Patients-with-Advanced-ROS1-positive-Non-Small-Cell-Lung-Cancer/default.aspx](https://investors.nuvationbio.com/news/news-details/2025/Nuvation-Bio-Receives-Approval-from-Japans-Ministry-of-Health-Labour-and-Welfare-for-IBTROZITM-for-Patients-with-Advanced-ROS1-positive-Non-Small-Cell-Lung-Cancer/default.aspx) Also, if you haven't seen, I created a new DD with the updated info: [https://www.reddit.com/r/wallstreetbets/comments/1njsjhv/nuvb\_100k\_yolo/](https://www.reddit.com/r/wallstreetbets/comments/1njsjhv/nuvb_100k_yolo/)
BREAKING News: NUVB IBTROZI is approved in Japan. i mentioned it in the DD, but i also expect sales to go on fast over there. the reason? Sauvage worked at Sanofi Japan and probably has a good book of contact. [https://investors.nuvationbio.com/news/news-details/2025/Nuvation-Bio-Receives-Approval-from-Japans-Ministry-of-Health-Labour-and-Welfare-for-IBTROZITM-for-Patients-with-Advanced-ROS1-positive-Non-Small-Cell-Lung-Cancer/default.aspx](https://investors.nuvationbio.com/news/news-details/2025/Nuvation-Bio-Receives-Approval-from-Japans-Ministry-of-Health-Labour-and-Welfare-for-IBTROZITM-for-Patients-with-Advanced-ROS1-positive-Non-Small-Cell-Lung-Cancer/default.aspx)
Impressive deep dive on NUVB. The Taletrectinib launch looks promising, especially with the NCCN recommendation. The conservative revenue projections and management's track record make this an interesting biotech play. Solid DD.
I’m long on NUVB too, love their leadership team.
TLDR. So just yolo all my money on NUVB?
Short answer: i still think it is a buy, the next earning in November we might see something big! Long answer: most of the bear cases were around how taletrectinib would a) not be approved (which it was) b) commercialization issues (which previous earnings have debunked), c) commercialization might burn cash faster than they bring revenue. \- commercialization of taletrectinib is high and based on the HC conference, might even beat expectations next earning. Note: No article seems to have caught that detail, stock didn't experience any kind of run up, so may be this was "priced in" \- The rest of the pipeline still holds significant risk: Safusidenib is the one of that could bring a lot of money to NUVB and they know it. They are trying to do a Head to head trial to show the superiority of their drug. Succeeding a phase 3 is extremely rare, hence why most people short clinical biotech rather than long it but assuming it works it's a 6B market \- Cash burn rate seems to be decent enough, i've done a few simulations but i want to wait november earnings to have a better feeling of how things would go onto next year The bears have valid reasons for concerns, i am more betting on teletrectinib killing it and the strong management. Safusidenib is the cherry on top. hope this helps, i am however always curious to know more bear view points
NUVB starting to rip. High short interest, good product, great leadership. $5+ 🔜
David spoke in investor’s conference after both trials’s updates (NUVB and NUVL) came out this weekend: https://journey.ct.events/view/ea2e92e3-d524-423c-a68a-fe84140ac942 His comments are encouraging and the results actually seem very good for NUVB. For second line treatment (comparing apples to apples as first line data for NUVL are preliminary), intracranial response is better with Ibtrozi (around 80% for NUVB vs below 50% for NUVL). Intracranial response is crucial in NSCLC and the reason for better efficacy of Ibtrozi could be that it still inhibits TRK which tend to affect tumor growth (this is just my hypothesis, could be because of drug potency/pharmacokinetice/brain penetration etc.). NUVL is ROS1 selective because the developers wanted to avoid TRK inhibition side effects, but it might just be the case that Ibtrozi hit a sweet spot (it is more selective for ROS1 compared to previus generation drugs to avoid dizzines but still not nearly as selective as zidesamtinib). David was also asked about the difference between NUVL and NUVB market cap (1,2 billion vs almost 6 billion), for which he sought an answer in Nuvalent presenting seemingly longer PFS with no real data to support it. I don’t think this is enough to explain the massive difference, but I cant think of a good answer.
NUVB 6.5$ will be sell for me 😉
What's up with NUVB? Im deep in atyr rn
I'm in NUVB, ANAB,CHRS, SPRY,PHAT. Also HUMA and HRTX, but these 2 I don't recommend
*high level summary, just my notes, do your own research always.* logged in to the HC Wainwright conference: \- David debunked NUVL hard hard hard LOL, he compared their study to: "putting 100 robots, letting them loose on a football pitch and watching just 3 of them cross the 22 yard mark and then claiming 22 as their median. " -> significant exlusion of population. David: "we don't do that here" \- David is curiously very very excited about the results of Safusedenib. for those who don't know the guy, he usually keeps himself humble and avoid overselling. Yet, he mentioned: "going for a Head to Head studies against Vorasidenib" and they are "in talk with the FDA". He seemed confident in Safusedenib for low grade glyoma. \- "Safusedenib have show a 70%" i think POF? couldn't get which metric he was talking about. David clearly believes that NUVB is superior to NUVL and that the data presented by NUVL is misleading and "most investors don't have knowledge about statistics" Sauvage: "Royalities" + "enough money for profitabilities prior to commercial lunch but that is still the case" D&S are excited about the future earnings report. Seeing that the expected is 7.5M revenue maybe they'll beat it? My 2cts: It's the 2nd time that David mentioned the H2H study and being in talk with the FDA for that. Yet NO NEWS picked up that crucial information. NO NEWS have debunked NUVL data and we have seen yesterday a huge drop in the stock. This feels like manipulation to me, do not sell wait for the earnings and see for yourself whether or not you trust the management.
FBIO and NUVB are false dips, trying to scare people off.
$CISO had a run up back to above $1 last week on Friday, keep watch on it as it may head towards $1.2 or up as it breaks resistance. $NUVB reached the 52 week high last Friday, may break out or may fall back down to build support. News released on Sunday on new data so watch for a price spike in PM.
FBIO. It's heavily shorted. I expect a false dip in the first hour of opening, to frighten people off, then an upward motion. The same with NUVB. CGTX can be had for less. Around 2.40/45 in a decent entry point.
their whole purpose is to make you buy their affiliated stocks. if you are curious about NUVB, you can check out my DD on it: [https://www.reddit.com/r/wallstreetbets/comments/1m3byk6/alright\_regards\_buckle\_up\_weve\_open\_the\_door\_now/](https://www.reddit.com/r/wallstreetbets/comments/1m3byk6/alright_regards_buckle_up_weve_open_the_door_now/) i add additional information every now and then on that thread. though NUVB has experienced a run, you should do your own research to know if it's worth investing your money
i don't know who OP is or what they posted but i made the first DD in wsb about NUVB months before the run up: [https://www.reddit.com/r/wallstreetbets/comments/1m3byk6/alright\_regards\_buckle\_up\_weve\_open\_the\_door\_now/](https://www.reddit.com/r/wallstreetbets/comments/1m3byk6/alright_regards_buckle_up_weve_open_the_door_now/) i still update that thread and maintain that NUVB will go way way way higher than the current price
Saw an interesting press release from $NUVL: [https://investors.nuvalent.com/nuvalent-presents-pivotal-data-from-arros-1](https://investors.nuvalent.com/nuvalent-presents-pivotal-data-from-arros-1) Nuvalent is positioning zidesamtinib as a refined ROS1 therapy that may outperform in **SPECIFIC** scenarios: brain metastases and resistance mutations. NUVB holds the upper hand with IBTROZI, zidesamtinib if approved could shift competitive dynamics. for now they are still playing catch up to NUVB but worth putting on a watchlist
Top 2 Health Care Stocks That May Plunge This Month BENZINGA - 09/05/2025 As of Sept. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. **Nuvation Bio Inc (NYSE:NUVB)** On Aug. 7, Nuvation Bio (NUVB) posted in-line loss for the second quarter. “With FDA approval of IBTROZI, we’re proud of our swift evolution into a commercial‐stage company executing across functions to deliver a differentiated therapy to 70 patients in just seven weeks,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio (NUVB). The company's stock gained around 44% over the past month and has a 52-week high of $3.48. RSI Value: 81.8 NUVB Price Action: Shares of Nuvation Bio (NUVB) gained 8.6% to close at $3.42 on Thursday.
Retirement plan = NUVB + hopium